Details for New Drug Application (NDA): 213644
✉ Email this page to a colleague
NDA 213644 describes TAZAROTENE, which is a drug marketed by Cosette, Fougera Pharms Inc, Padagis Israel, Taro, and Solaris Pharma Corp, and is included in eight NDAs. It is available from six suppliers. Additional details are available on the TAZAROTENE profile page.
The generic ingredient in TAZAROTENE is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
The generic ingredient in TAZAROTENE is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
Summary for 213644
| Tradename: | TAZAROTENE |
| Applicant: | Solaris Pharma Corp |
| Ingredient: | tazarotene |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213644
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TAZAROTENE | tazarotene | GEL;TOPICAL | 213644 | ANDA | Solaris Pharma Corporation | 73473-309 | 73473-309-10 | 1 TUBE in 1 CARTON (73473-309-10) / 100 g in 1 TUBE |
| TAZAROTENE | tazarotene | GEL;TOPICAL | 213644 | ANDA | Solaris Pharma Corporation | 73473-309 | 73473-309-30 | 1 TUBE in 1 CARTON (73473-309-30) / 30 g in 1 TUBE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | Mar 20, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;TOPICAL | Strength | 0.1% | ||||
| Approval Date: | Mar 20, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
